Susquehanna International Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Susquehanna International Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.95M	Buy	265,600 +69,900	+36%	+$1.16M	﹤0.01%	4246
2025 Q4	$2.58M	Buy	195,700 +87,600	+81%	+$1.03M	﹤0.01%	5149
2025 Q3	$775K	Buy	108,100 +25,700	+31%	+$1.34M	﹤0.01%	7946
2025 Q2	$3.89M	Buy	82,400 +75,600	+1,112%	+$3.08M	﹤0.01%	4453
2025 Q1	$266K	Sell	6,800 -19,300	-74%	-$832K	﹤0.01%	10330
2024 Q4	$1.41M	Buy	26,100 +12,400	+91%	+$633K	﹤0.01%	6099
2024 Q3	$691K	Sell	13,700 -30,700	-69%	-$1.44M	﹤0.01%	7687
2024 Q2	$1.95M	Sell	44,400 -81,500	-65%	-$3.45M	﹤0.01%	5144
2024 Q1	$6.32M	Buy	125,900 +38,300	+44%	+$2.08M	﹤0.01%	3258
2023 Q4	$5.29M	Sell	87,600 -26,900	-23%	-$1.39M	﹤0.01%	3616
2023 Q3	$6.53M	Buy	+114,500	New	+$6.32M	﹤0.01%	3118

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group's MLTX Position: Q1 2026 in Review

Susquehanna International Group reduced its MoonLake Immunotherapeutics (MLTX) stake by 38% in Q1 2026, selling an estimated $3.44M and leaving 341,424 shares worth $6.36M. The position accounts for ﹤0.01% of the portfolio, ranked #3838.

Susquehanna International Group first reported a position in MLTX in Q3 2023 and has held it in 7 quarters since. The position peaked at $12.9M in Q4 2023. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

Susquehanna International Group held 341,424 shares of MoonLake Immunotherapeutics worth $6.36M as of Q1 2026.
Susquehanna International Group sold 207,812 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $3.44M.
MoonLake Immunotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3838 holding.
Susquehanna International Group first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 7 quarters since.
Susquehanna International Group's MoonLake Immunotherapeutics position peaked at $12.9M in Q4 2023.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.